Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Arecor Therape (AREC)

Price 137.50p on 28-03-2024 at 09:00:12
Change 0.00p 0%
Buy 140.00p
Sell 135.00p
Buy / Sell AREC Shares
Last Trade: Sell 4,000.00 at 135.11p
Day's Volume: 6,500
Last Close: 137.50p
Open: 137.50p
ISIN: GB00BMWLM973
Day's Range 137.50p - 137.50p
52wk Range: 132.50p - 276.00p
Market Capitalisation: £42m
VWAP: 135.11p
Shares in Issue: 31m

Recent Trades History Arecor Therape (AREC)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 4,000 135.11p Ordinary
08:11:33 - 28-Mar-24
Sell* 2,500 135.11p Ordinary
08:02:15 - 28-Mar-24

Share Price History for Arecor Therape

Time period:
to
Date Open High Low Close Volume

Share News for Arecor Therape

Arecor to develop "holy grail" diabetes treatment with partner TRx

12th Mar 2024 12:16

(Alliance News) - Arecor Therapeutics PLC on Tuesday announced a new partnership in the growing field of diabetes and obesity treatments. Read More

EARNINGS AND TRADING: East Star, Getech strike Kazakhstan JV

29th Feb 2024 19:42

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Arecor Therapeutics hails Arestat as 2023 performance "strong"

1st Feb 2024 14:24

(Alliance News) - Arecor Therapeutics PLC on Thursday celebrated a "strong commercial performance" for 2023, touting the first commercial product incorporating its platform Arestat. Read More

IN BRIEF: Arecor pleased as investee Inhibrx sells therapy to Sanofi

23rd Jan 2024 21:47

Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Notes announcement from Inhibrx Inc and Sanofi SA that both companies have agreed Sanofi will acquires all assets and liabilities associated with INBRX-101. INBRX-101 is an optimised recombinant alpha-1 antitrypsin augmentation therapy, currently undergoing a residential trial treating patients with alpha-11 antitrypsin deficiency or AATD. INBRX-101 incorporates "a novel enhanced formulation" developed by Arecor using its patented Arestat technology. Arecor and Inhibrx entered a license agreement in December 2020. Read More

TRADING UPDATES: Patent boosts for DG Innovate and Arecor Therapeutics

18th Jan 2024 18:26

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value7,970.74
Change38.76

Login to your account

Forgot Password?

Not Registered